Braveheart Bio Strengthens Leadership with Emil deGoma, M.D. as CMO for Innovative Cardiovascular Therapeutics

Braveheart Bio Appoints Emil deGoma, M.D., as Chief Medical Officer

Braveheart Bio, a pioneering clinical-stage biotechnology company, has announced the appointment of
Dr. Emil deGoma as its new Chief Medical Officer. This strategic move is part of the company's ongoing efforts to enhance its leadership team as it progresses towards the initiation of a pivotal global trial for its innovative therapeutic, BHB-1893, aimed specifically at obstructive hypertrophic cardiomyopathy (oHCM).

Dr. deGoma's extensive background in cardiology and his previous leadership roles within the industry make him an excellent fit for this position. Travis Murdoch, M.D., the CEO and President of Braveheart Bio, emphasized that Emil’s experience in guiding clinical programs will be vital in delivering BHB-1893, positioning it as a potential new treatment option for patients suffering from hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions.

Dr. deGoma previously served as the Senior Vice President of Medical Research at Tourmaline Bio, where he was instrumental in managing development strategies and executing clinical trials. He has also held significant roles at Akebia Therapeutics, overseeing trials involving over 7,000 patients, and at ChemoCentryx and Penn Medicine at the University of Pennsylvania. His academic credentials are equally impressive, having earned his A.B. in Biochemical Sciences from Harvard College and his M.D. from Harvard Medical School, along with completing his internal medicine residency and cardiovascular fellowship at Stanford University. He is recognized as a Fellow of both the American College of Cardiology and the American Heart Association.

Expressing his enthusiasm about joining Braveheart Bio, Dr. deGoma stated, "Hypertrophic cardiomyopathy remains a major unmet need in cardiovascular medicine, and I'm excited to join Braveheart at such a pivotal moment in the development of BHB-1893. The opportunity to help advance a potentially best-in-class therapy for patients living with hypertrophic cardiomyopathy is truly exciting. I look forward to collaborating with the talented team at Braveheart to advance BHB-1893 through global development."

The clinical focus of Braveheart Bio revolves around its primary product candidate, BHB-1893, which is currently in the late-stage clinical development phase. The company aims to set a new standard of care for hypertrophic cardiomyopathy, a condition characterized by abnormal thickening of the heart muscle, which can lead to serious complications, including heart failure and sudden cardiac death.

Braveheart Bio is backed by prominent life science investors, including Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences, and Frazier Life Sciences, which strengthens its capacity to innovate within the cardiovascular therapeutic space.

As Braveheart Bio prepares to embark on this ambitious journey of advancing BHB-1893, the expertise and leadership of Emil deGoma as Chief Medical Officer will be crucial to harnessing the potential of this promising therapeutic option. His arrival marks a significant step forward for the company as it aims to address the cardiovascular needs of patients worldwide.

To learn more about Braveheart Bio and its innovative approaches to treating hypertrophic cardiomyopathy, visit braveheart.bio.